Of 70 patients who received first‐line LEN treatment, 55 patients experienced disease progression, and 15 patients discontinued treatment due to adverse events (grade 3/4 bilirubin increase, grade 4 hypertension, grade 3 ALT/AST elevation, and proteinuria). The gene discussed is GPT; the disease is Hypertension.